Business · 25/05/2007Updated: 10/17/2026 · 1 min read
FDA Determines Regulatory Review Periods for SPRYCEL New Drug Applications
Summary
The Food and Drug Administration (FDA) has officially confirmed the review period for SPRYCEL's new drug applications (NDAs) 21-986 and 22-072, as required by law, following a patent extension application submitted to the Director of Patents and Trademarks at the Department of Commerce.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →